Preferences & Treatment Satisfaction Drivers in Rosacea Patients

LEO Pharma206 enrolled

Overview

To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.

Study Type

OBSERVATIONAL

Enrollment

206

Conditions

Rosacea

Interventions

Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)DRUG

Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing

Azelaic Acid CreamDRUG

Azelaic Acid Cream 20%

Metronidazole gelDRUG

Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients of at least 18 years of age at index date * At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel * At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3) * At least 6 months of data history prior to the index date * Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015 Exclusion Criteria: * None

Locations (1)

Unnamed facility

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Self-reported concerns and importance of such concerns regarding their current topical rosacea treatments

Assessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely important